Copyright
©2014 Baishideng Publishing Group Inc.
World J Clin Oncol. Aug 10, 2014; 5(3): 393-405
Published online Aug 10, 2014. doi: 10.5306/wjco.v5.i3.393
Published online Aug 10, 2014. doi: 10.5306/wjco.v5.i3.393
Table 4 Frequency of subjective adverse events among 499 patients with invasive breast cancer randomised to adjuvant toremifene or tamoxifen therapy[33]
| Toremifene | Tamoxifen | |||
| Number of patients | % | Number of patients | % | |
| Sweating | 247 | 53.8 | 225 | 51.1 |
| Hot flashes | 237 | 51.6 | 209 | 47.5 |
| Vaginal discharge | 193 | 42.0 | 156 | 35.5 |
| Vaginal dryness | 120 | 26.1 | 117 | 26.6 |
| Itching | 118 | 25.7 | 119 | 27.0 |
| Depression | 112 | 24.4 | 119 | 27.0 |
| Rash | 90 | 19.6 | 75 | 17.0 |
| Nausea | 78 | 17.0 | 85 | 19.3 |
| Vaginal bleeding | 40 | 8.7 | 37 | 8.4 |
| Diarrhea | 37 | 8.1 | 51 | 11.6 |
| Weight increase | 23 | 5.0 | 19 | 4.3 |
- Citation: Mustonen MV, Pyrhönen S, Kellokumpu-Lehtinen PL. Toremifene in the treatment of breast cancer. World J Clin Oncol 2014; 5(3): 393-405
- URL: https://www.wjgnet.com/2218-4333/full/v5/i3/393.htm
- DOI: https://dx.doi.org/10.5306/wjco.v5.i3.393